Zenjiro Sampei

Title: Zenjiro Sampei: Innovator in Anti-Dengue Virus Research

Introduction

Zenjiro Sampei is a notable inventor based in Shizuoka, Japan. He has made significant contributions to the field of virology, particularly in the development of treatments for dengue virus infections. His innovative work has led to the creation of valuable patents that aim to combat viral diseases.

Latest Patents

Zenjiro Sampei holds a patent for "Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use." This patent provides a comprehensive disclosure of anti-DENV antibodies and methods for their production and application. The invention includes nucleic acids encoding these antibodies and host cells that incorporate them. The anti-DENV antibodies are designed for use in treating dengue virus infections. Additionally, the patent covers polypeptides with variant Fc regions, which also have applications in treating viral infections. Notably, the polypeptides are characterized by a Fc variant that has specific amino acid alterations, resulting in decreased FcYR-binding activity while maintaining C1q-binding activity.

Career Highlights

Throughout his career, Zenjiro Sampei has worked with prominent organizations, including Chugai Seiyaku Kabushiki Kaisha and the Agency for Science, Technology and Research. His experience in these institutions has contributed to his expertise in the field of biotechnology and virology.

Collaborations

Zenjiro has collaborated with notable colleagues, including Xing'er Christine Koo and Katja Fink. These partnerships have likely enhanced his research and development efforts in the field of anti-viral therapies.

Conclusion

Zenjiro Sampei's innovative work in developing anti-dengue virus treatments showcases his commitment to advancing medical science. His contributions through patents and collaborations highlight the importance of research in combating viral infections.